Table 2.
Characteristics of patients in randomized clinical trials.
| Age | FIGO | Platinum-Free Interval | Previous Bevacizumab | Histology | |
|---|---|---|---|---|---|
| DESKTOP III | SCS 60.8 (54.2–67.3) | III 145 (70.4%) IV 16 (7.8%) |
6–12 m 48 (23.6%) >12 m 155 (76.4%) |
33 (16%) | Serous 177 (85.9%) Other 23 (14.1%) |
| No SCS 62.2 (54.2–69.9) | III 143 (71.1%) IV 13 (6.5%) |
6–12 m 47 (23.7%) >12 m 151 (76.3%) |
31 (15.4%) | Serous 161 (80.1%) Other 40 (19.9%) |
|
| GOG 0213 | SCS <60 years 135 (56.2%) >60 years 105 (43.8%) |
NE | NE | 25 (10.4%) | Serous 211 (87%) Other 29 (12.3%) |
| No SCS <60 years 145 (59.1%) >60 years 100 (40.8%) |
30 (12.2%) | Serous 207 (84.5%) Other 38 (15.5%) |
|||
| SOC-1 | SCS <54 years 80 >54 years 102 |
III 128 IV 20 |
NE | NE | Serous 158 Another 24 |
| No SCS <54 years 90 >54 years 85 |
III 121 IV 25 |
Serous 145 Another 30 |